# Sundia MediTech Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sundia-meditech-company

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.sundia.com
- Total disclosed funding: $2.4M
- Latest round: Series B (Jan 17, 2008)
- Investors on record: 3

## About

Sundia MediTech Company, Ltd. specializes in integrated drug discovery and development services, catering to the pharmaceutical and biotechnology sectors with innovative solutions.Founded in 2004 in Shanghai, China, Sundia MediTech Company, Ltd. focuses on drug development and has participated in 3 deals, with the latest being a Series A round of CNY 20.000 mn led by IDG Capital. In September 2020, BioDuro-Sundia acquired a majority stake in Sundia, indicating a strategic shift to enhance their drug development capabilities.Sundia MediTech offers a comprehensive suite of drug discovery and development services tailored for pharmaceutical and biotechnology companies. Their core offerings include Drug Substance and Drug Product development, Antibody-Drug Conjugates, Peptide Compound Management, and PROTAC solutions. These services cover the entire drug development lifecycle, particularly focusing on oncology and pharmacology applications, and cater to clients across North America, Europe, and Asia-Pacific, employing advanced technologies such as DNA-Encoded Libraries and MASH Mouse Models.Sundia MediTech generates revenue through project-based contracts and strategic partnerships within the pharmaceutical and biotechnology sectors. Their revenue model is based on long-term collaborations with milestone-based payments, including upfront fees tied to specific development milestones. The company’s flagship services are offered in holistic packages that may also involve ongoing support and consultation, allowing for tailored pricing arrangements to meet client needs.Sundia MediTech plans to leverage recent funding to expand its product offerings and market reach. The recent acquisition by BioDuro-Sundia aims to enhance its drug development services and explore new therapeutic areas. Furthermore, the company targets market expansion initiatives in the Asia-Pacific region, specifically looking to establish a stronger foothold in key biotech hubs by the end of 2023. The CNY 20.000 mn raised in the Series A funding round will support these growth strategies.

## Funding rounds

- Series B, Jan 17, 2008 — Japan Asia Investment Company, AsiaVest Partners, IDG Capital
- Series A, Jul 1, 2005, $2.4M — IDG Capital

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A, Series B
- Japan Asia Investment Company (https://capitalatlas.ai/funds/japan-asia-investment-company) — Series B
- AsiaVest Partners — Series B